Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares: 2019-2025

Historic Treasury Shares for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $1.4 million.

  • Kymera Therapeutics' Treasury Shares rose 74.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 74.39%. This contributed to the annual value of $749,604 for FY2024, which is 26.38% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Treasury Shares of $1.4 million as of Q3 2025, which was up 7.14% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Treasury Shares peaked at $1.4 million during Q3 2025, and registered a low of $37,745 during Q4 2021.
  • Its 3-year average for Treasury Shares is $804,231, with a median of $725,438 in 2024.
  • In the last 5 years, Kymera Therapeutics' Treasury Shares tumbled by 65.72% in 2021 and then skyrocketed by 646.70% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Treasury Shares (Quarterly) stood at $37,745 in 2021, then surged by 646.70% to $281,843 in 2022, then skyrocketed by 110.45% to $593,140 in 2023, then increased by 26.38% to $749,604 in 2024, then skyrocketed by 74.39% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.2 million during Q1 2025.